NCT00828971 - A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2009

Conditions

Infectious Diseases

Interventions

DRUG

Avelox (Moxifloxacin, BAY12-8039)

Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.

DRUG

Amoxicilline/clavulanic

IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days

Trial Locations (22)

10149

Torino

16132

Genova

21100

Varese

24128

Bergamo

25123

Brescia

33100

Udine

35128

Padua

37126

Verona

40138

Bologna

42100

Reggio Emilia

44100

Ferrara

46100

Mantova

47900

Rimini

50100

Bagno Di Ripoli

50139

Florence

70124

Bari

71100

Foggia

80131

Napoli

98158

Messina

06122

Perugia

00149

Roma

00168

Roma